DexCom (NASDAQ:DXCM) Upgraded at StockNews.com

DexCom (NASDAQ:DXCMGet Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Monday.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. reduced their price target on shares of DexCom from $160.00 to $100.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 17th. Piper Sandler increased their price target on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Raymond James increased their price target on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Wells Fargo & Company increased their price target on shares of DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of DexCom in a research report on Monday, October 16th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $134.64.

Check Out Our Latest Research Report on DexCom

DexCom Trading Down 1.7 %

Shares of DXCM stock traded down $2.05 on Monday, hitting $118.42. The stock had a trading volume of 5,251,722 shares, compared to its average volume of 2,818,336. DexCom has a twelve month low of $74.75 and a twelve month high of $139.55. The firm has a market cap of $45.65 billion, a P/E ratio of 90.40, a PEG ratio of 2.33 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The company has a fifty day moving average price of $123.34 and a two-hundred day moving average price of $108.34.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business earned $0.34 EPS. DexCom’s quarterly revenue was up 26.9% on a year-over-year basis. As a group, analysts forecast that DexCom will post 1.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 2,902 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total value of $358,774.26. Following the completion of the sale, the executive vice president now owns 79,051 shares of the company’s stock, valued at approximately $9,773,075.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other DexCom news, CFO Jereme M. Sylvain sold 2,734 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $123.63, for a total value of $338,004.42. Following the completion of the transaction, the chief financial officer now directly owns 74,505 shares in the company, valued at approximately $9,211,053.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 2,902 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $358,774.26. Following the completion of the transaction, the executive vice president now owns 79,051 shares of the company’s stock, valued at $9,773,075.13. The disclosure for this sale can be found here. Insiders sold a total of 58,098 shares of company stock valued at $7,091,785 in the last quarter. Corporate insiders own 0.41% of the company’s stock.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently modified their holdings of the business. Bartlett & Co. LLC purchased a new stake in DexCom during the 4th quarter valued at about $27,000. DSM Capital Partners LLC purchased a new stake in DexCom during the 4th quarter valued at about $28,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Harbour Investments Inc. grew its position in DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 120 shares during the last quarter. Finally, Atlas Capital Advisors LLC purchased a new stake in DexCom during the 2nd quarter valued at about $33,000. 93.88% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

(Get Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.